Galera Therapeutics, Inc. (GRTX)

0.1860 -0.0124 (-6.25%) At close: 04:00PM EDT

Galera Therapeutics, Inc.

P.O. Box 134
Malvern, PA 19355
United States
610 725 1500
https://www.galeratx.com

Sector(s): Healthcare
Industry: Biotechnology
Full-time employees: 7

Key executives

Name	Title	Pay	Exercised	Year born
Dr. J. Mel Sorensen M.D.	CEO, President & Director	632.64k	N/A	1957
Dr. Robert A. Beardsley M.B.A., Ph.D.	Co-Founder & COO	464.59k	N/A	1962
Mr. Christopher Degnan	Chief Financial Officer	474.05k	N/A	1980
Ms. Jennifer Evans Stacey Esq.	Chief Legal & Compliance Officer and Secretary	N/A	N/A	1965
Ms. Andie Collier	Chief Regulatory & Quality Affairs Officer	N/A	N/A	N/A
Ms. Judy Schnyder	Senior Vice President of Clinical Operations & Data Management	N/A	N/A	N/A

Amounts are as of 31 December 2023, and compensation values are for the last fiscal year ending on that date. Pay includes salary, bonuses, etc. Exercised is the value of options exercised during the fiscal year. Currency in USD.

Description

Galera Therapeutics, Inc., a clinical stage biopharmaceutical company, focuses on the development and commercialization of therapeutics for the transformation of radiotherapy in cancer. The company's lead product candidate is avasopasem manganese (GC4419), a small molecule dismutase mimetic, which has completed Phase III clinical trial for the treatment of radiotherapy induced severe oral mucositis in patients with head and neck cancer (HNC); in Phase IIa clinical trial for the treatment of radiotherapy-induced esophagitis in patients with lung cancer; and in Phase IIa clinical trial for patients with HNC undergoing standard-of-care radiotherapy. It is also developing GC4711, a dismutase mimetic product candidate, which is in Phase I/II clinical trial in combination with stereotactic body radiation therapy in patients with non-small cell lung cancer and locally advanced pancreatic cancer. The company was incorporated in 2012 and is based in Malvern, Pennsylvania.

Corporate governance

Galera Therapeutics, Inc.’s ISS governance QualityScore as of 1 April 2024 is 8. The pillar scores are Audit: 8; Board: 8; Shareholder rights: 7; Compensation: 8.

Corporate governance scores courtesy of Institutional Shareholder Services (ISS). Scores indicate decile rank relative to index or region. A decile score of 1 indicates lower governance risk, while 10 indicates higher governance risk.